Why Keiretsu Forum Mid-Atlantic?

“Keiretsu” is the Japanese word for a family of affiliated companies that form a tight-knit alliance and work toward each other’s mutual success. Consistent with this definition, Keiretsu Forum is a conglomeration of serious investors, business leaders, venture capitalists, corporate/institutional investors and serial entrepreneurs bound by two overlapping and codependent goals:

To work together for each other’s mutual benefit, forming strategic partnerships, enhancing each other’s knowledge and building an angel network of diverse skills

With more than 2,800 accredited angel investor members dispersed throughout 52 chapters on three continents, Keiretsu Forum is the world’s largest and most successful accredited investor – private equity community. Since Keiretsu Forum’s founding in 2000, its members have invested more than $950 million in 900+ different companies from a myriad of industries, including software, telecommunications, health/life sciences, biotech, real estate, mobile applications, Internet, consumer products and other high growth areas.

LEARN MORE ABOUT KEIRETSU FORUM

Knowledge is power in pretty much every aspect of life, but especially when it comes to your business and angel investment decisions. Keiretsu Forum makes it easy for you to stay informed and up-to-date on everything going on in the world of private equity and startup business development.

Membership in Keiretsu Forum Mid-Atlantic Chapters is by invitation only. This invitation is extended to individuals who share Keiretsu Forum’s value for innovation, commitment to collaboration, enthusiasm for ethics, devotion to diligence and spirit for social consciousness.

“Keiretsu Forum takes a disciplined and comprehensive approach to deal screening and due diligence for their investors. Their process allows companies to access a large group of sophisticated investors, while allowing Keiretsu members to access quality deals. The enthusiasm Savara received has been tremendous; allowing us to proceed with a Phase II clinical trial in MRSA infected cystic fibrosis patients without the need for VC funding! With Keiretsu Forum’s chapters taking the lead, Savara raised over $39m from angel investors!”